[ Inside the business ]

TWST stock analysis

TWST · Twist Bioscience Corp

Biological products, (no diagnostic substances). Growing 28%. Loses 30¢ on every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#2 of 20 mentioning it
03 Will customers keep buying?Sales +28%, speeding up
No customer over 10%
Backlog $22M · under 0.1× salesPrepaid $7MSales +28%, speeding up
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 37% → 52%
06 Can it fund itself?6.5 yrs of cash
05 yrs10+ yrs
Shares +3.9%/yrDebt $0
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +19%, +23%, then +28% vs. a year ago.

What could go wrong

Falls harder.

It has moved 1.6× the market. In the 2022 rate shock it fell 54% while the market fell 24%. Debt is covered by cash.

Speculative check

Speculative.

Speculative: operating loss, cash flowing out of operations, under $1B in sales. Cash runway: 6.5 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

30¢ loss.

48¢ to make what it sells, 83¢ on research and overhead, nothing left over. Revenue $459M in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Introduction.

It uses cash, invests, and raises money to keep going.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

0 of 8 years.

Returns beat its 13.1% cost of capital in 0 of the last 8 years. Gross margin went from -123% to 52%.

Future bets

16% on research.

$72M a year on R&D. $48M on equipment and buildings.

All figures from Twist Bioscience Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.